A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate * Radiographically documented metastatic disease with evidence of disease progression Laboratory parameters per protocol * Surgically or medically castrate * Patients who have progressed following: * a. at least initial therapy (chemotherapy or treatment with a hormonal agent known to impact survival such as abiraterone and enzalutamide); or * b. one first-line chemotherapy regimen and one additional hormonal agent known to impact survival such as abiraterone and enzalutamide; or * c. failure of two lines of chemotherapy; or * d. failure of pre-chemotherapy abiraterone or enzalutamide and subsequent chemotherapy Exclusion Criteria: * Patients with neuroendocrine or small cell cancer of the prostate 2. History of other malignant disease (with the exception of the primary prostate cancer and non-melanoma skin tumors) in the past 5 years Pre-defined co-morbidities * Administration of experimental therapy within the last 4 weeks before start of screening * Treatment with immunotherapy within the last 3 months before start of screening * Treatment with radiopharmaceutical drugs within 8 weeks before start of screening * Receipt of oncolytic virus treatment or vaccination with a live virus within 4 weeks of study start * History of organ transplantation